Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide

Yosuke Okamura, Toshinori Fujie, Hitomi Maruyama, Makoto Handa, Yasuo Ikeda, Shinji Takeoka

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

    Original languageEnglish
    Pages (from-to)1254-1262
    Number of pages9
    JournalTransfusion
    Volume47
    Issue number7
    DOIs
    Publication statusPublished - 2007 Jul

    Fingerprint

    Hemostatics
    Fibrinogen
    Albumins
    Bleeding Time
    Tail
    Hemorrhage
    Platelet Transfusion
    Blood Circulation
    Blood Platelets
    Injections
    Therapeutics

    ASJC Scopus subject areas

    • Hematology
    • Immunology

    Cite this

    Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide. / Okamura, Yosuke; Fujie, Toshinori; Maruyama, Hitomi; Handa, Makoto; Ikeda, Yasuo; Takeoka, Shinji.

    In: Transfusion, Vol. 47, No. 7, 07.2007, p. 1254-1262.

    Research output: Contribution to journalArticle

    Okamura, Yosuke ; Fujie, Toshinori ; Maruyama, Hitomi ; Handa, Makoto ; Ikeda, Yasuo ; Takeoka, Shinji. / Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide. In: Transfusion. 2007 ; Vol. 47, No. 7. pp. 1254-1262.
    @article{ffa6f9190f904f1f84be6c2c52432d12,
    title = "Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide",
    abstract = "BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.",
    author = "Yosuke Okamura and Toshinori Fujie and Hitomi Maruyama and Makoto Handa and Yasuo Ikeda and Shinji Takeoka",
    year = "2007",
    month = "7",
    doi = "10.1111/j.1537-2995.2007.01265.x",
    language = "English",
    volume = "47",
    pages = "1254--1262",
    journal = "Transfusion",
    issn = "0041-1132",
    publisher = "Wiley-Blackwell",
    number = "7",

    }

    TY - JOUR

    T1 - Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen γ-chain dodecapeptide

    AU - Okamura, Yosuke

    AU - Fujie, Toshinori

    AU - Maruyama, Hitomi

    AU - Handa, Makoto

    AU - Ikeda, Yasuo

    AU - Takeoka, Shinji

    PY - 2007/7

    Y1 - 2007/7

    N2 - BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

    AB - BACKGROUND: Second-generation platelet (PLT) substitutes for treatment of bleeding were studied and the focus was on a dodecapeptide, HHLGGAKQAGDV (H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ 400-411) and exists only in a fibrinogen domain. STUDY DESIGN AND METHODS: H12 was conjugated to the surface of polymerized albumin particles (polyAlb) modified with polyethylene glycol (PEG) chains to produce biocompatible particles (H12-PEG-polyAlb) that had prolonged blood circulation t1/2 and were more stable in vitro and in vivo compared with H12-polyAlb (not modified with PEG). H12-PEG-polyAlb was administered intravenously into thrombocytopenic rats and the t1/2 of the particles and the tail bleeding time were measured to evaluate the prolongation in the hemostatic effect. RESULTS: H12-PEG-polyAlb particles modified with PEG prolonged the t1/2 and maintained specific binding ability to activated PLTs. The particles dose dependently shortened the tail bleeding time of thrombocytopenic rats 6 hours after injection. CONCLUSION: H12-PEG-polyAlb may be a suitable candidate for treatment of bleeding into thrombocytopenic patients as an alternative to PLT concentrate transfusion.

    UR - http://www.scopus.com/inward/record.url?scp=34250688226&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=34250688226&partnerID=8YFLogxK

    U2 - 10.1111/j.1537-2995.2007.01265.x

    DO - 10.1111/j.1537-2995.2007.01265.x

    M3 - Article

    C2 - 17581161

    AN - SCOPUS:34250688226

    VL - 47

    SP - 1254

    EP - 1262

    JO - Transfusion

    JF - Transfusion

    SN - 0041-1132

    IS - 7

    ER -